Connect with us

archive

Pfizer 3Q Earnings Powered by Oncology, Beat Estimates

Pfizer 3Q Earnings Powered by Oncology, Beat Estimates (Reuters)

The United States’ largest drug maker, Pfizer Inc., reported that Q3 earnings beat estimates. The company earned $2.59 billion for the quarter, or 58 cents per share (excluding special items), while analysts had predicted 56 cents per share. Much of the additional profit came from a 26 percent pop in oncology drug sales, which totaled $407 million for the quarter. However, global sales for the period fell 7 percent to $12.64, due to generic competition for Lipitor and other drugs. Wall Street had expected sales of $12.7 billion. Investors in Pfizer now have to ask themselves if they can see momentum continuing at that fervid pace for oncology drugs, and if that will be enough to overcome lagging global sales. If you come up with a good answer, please let us know by commenting below.

Advertisement
Advertisement

TRENDING NOW:

THE TRUTH ABOUT GLOBAL WARMING: REAL THREAT OR HYSTERIA?

archive

Dystopia Alert: A Decimating National Debt

archive

Guest Columnist: Why We Must Have a Border Wall

archive

Rising Social Agenda Brings Luster to Qualified Dividends

archive

archive

Pfizer 3Q Earnings Powered by Oncology, Beat Estimates

The United States‚?? largest drug maker, Pfizer Inc., reported that Q3 earnings beat estimates.

Pfizer 3Q Earnings Powered by Oncology, Beat Estimates (Reuters)

The United States‚?? largest drug maker, Pfizer Inc., reported that Q3 earnings beat estimates. The company earned $2.59 billion for the quarter, or 58 cents per share (excluding special items), while analysts had predicted 56 cents per share. Much of the additional profit came from a 26 percent pop in oncology drug sales, which totaled $407 million for the quarter. However, global sales for the period fell 7 percent to $12.64, due to generic competition for Lipitor and other drugs. Wall Street had expected sales of $12.7 billion. Investors in Pfizer now have to ask themselves if they can see momentum continuing at that fervid pace for oncology drugs, and if that will be enough to overcome lagging global sales. If you come up with a good answer, please let us know by commenting below.

Written By

TRENDING NOW:

Connect